Scinovex
articleTop 1% cited

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Diabetes Care · 2005 · Vol. 28(5) · pp. 1092–1100
Ralph A. DeFronzoRobert E. RatnerJenny HanDennis Dong Hwan KimMark FinemanAlain Baron

Abstract

Exenatide was generally well tolerated and reduced HbA(1c) with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin.

Diabetes Treatment and ManagementDiabetes Management and ResearchMetabolism, Diabetes, and CancerExenatideMedicineMetforminPlaceboGlycemicHypoglycemiaInternal medicineType 2 diabetesDiabetes mellitusPopulation

MeSH terms

ExenatideAdultAgedBlood GlucoseBody WeightDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsInsulinMaleMetformin

Funding

  • Amylin Pharmaceuticals
  • U.S. Food and Drug Administration
Citations
1,553
FWCI
73.08
field-weighted impact
References
37
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.